Product Images Imatinib Mesylate

This is a statistical report showing data related to progression, censoring, hazard ratio, log-rank test, and comparison between two arms in a study conducted over 72 months since randomization. The information in the text seems to be related to medical or clinical research, but specific details on the study are not clear from the provided text.*

This text provides information on the treatment outcome of patients with Imatinib Mesylate who progressed to Accelerated Phase (AP) or Blast Crisis (BC). The hazard ratio and log-rank test results are also presented, indicating a statistically significant difference between the treatment groups. The data is presented over different time intervals since randomization, helping to understand the progression of the disease under study.*

This is a description of a medication called Imatinib Mesylate, which comes in a pack of 90 tablets with each tablet containing 100 mg of imatinib free base. The dosage and storage instructions are provided, along with the note that it is a prescription medication. It is recommended to keep the medication in a container defined by the USP regulations and to keep it out of reach of children. The product is distributed by Upsher-Smith Laboratories, LLC.*

This is a pharmaceutical label containing information about a medication. Each tablet contains 400 mg of the active ingredient. The storage instructions indicate to store the medicine between 20° to 25°C (68° to 77°F) with excursions permitted between 15° to 30°C (59° to 86°F). The medication is formulated based on USP guidelines for room temperature and should be protected from moisture. It should be dispensed in a tight container as defined in the USP. The manufacturer is UPSHER-SMITH LABORATORIES located in Wape Grove, MN 55369. The copyright date on the label is 2024. The label states that the medication is for prescription use only and contains 30 tablets in total.*